TP53 and neoplasm: Although murine cell lines possessing tumorigenic eligibility can be used as preclinical models for immune and drug tests, since MPC-1 is p53 deficient, this cell line is likely to be useful when addressing tumor pathogenesis via restoration of p53 functionality [15,16].